21269-34-1Relevant articles and documents
3,6-DISUBSTITUTED-2-PYRIDINALDOXIME SCAFFOLDS
-
Paragraph 0095; 0153-0155, (2020/08/27)
The present invention relates to a compound of formula (I), or one of its pharmaceutically acceptable salts: wherein R1, R2 and -X-Y- have specific definitions. It also relates to the use of such a compound as reactivator of acetylcholinesterase for treating organophosphorous nerve agents poisoning; and to a process for preparing it.
Organic optoelectronic functional material and application thereof
-
, (2019/01/06)
The invention belongs to the field of organic electroluminescent devices, and discloses an organic electroluminescent material containing a diquinolyl structure and application of the organic electroluminescent material. By using the organic electroluminescent material provided by the invention as an electron transport material, the produced device has good electron mobility and relatively-balanced current carrier transmission property, and the improvement efficiency of the device is facilitated. In addition, the organic electroluminescent material provided by the invention also can be furtherblended with a hole type main body material so as to form an exciplex; by using the exciplex as a co-subject material, the efficiency and the stability of the produced device are both improved obviously.
Synthesis and anti-tumor activities of 4-anilinoquinoline derivatives
Liu, Dan,Luan, Tian,Kong, Jian,Zhang, Ying,Wang, Hai-Feng
, (2016/02/05)
Twenty-two 7-fluoro (or 8-methoxy)-4-anilinoquinolines compounds were designed and synthesized as potentially potent and selective antitumor inhibitors. All the prepared compounds were evaluated for their in vitro antiproliferative activities against the HeLa and BGC823 cell lines. Ten compounds (1a-g; 2c; 2e and 2i) exhibited excellent antitumor activity superior to that of gefitinib. Among the ten compounds; seven (1a-c; 1e-1g and 2i) displayed excellent selectivity for BGC823 cells. In particular; 1f and 2i exhibited potent cytotoxic activities against HeLa cells and BGC823 cells with better IC50 values than gefitinib.